Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

Thankfully the symbols they use are (mostly) universal, so once you've learned what each represents (as we explain below) you shouldn't have any problems no matter what you find in your laundry basket ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

This important work identifies a non-autophagic role for ATG5 in lysosomal repair and the trafficking of the glucose transporter GLUT1 to the cell surface, mediated through the retromer complex. The ...

The paper investigates a potential cause of a type of severe epilepsy that develops in early life because of a defect in a gene called KCNQ2. The significance is fundamental because it substantially ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Our study examined the mutation efficiency of the CRISPR/Cas9 method for tryptophan aminotransferase BnaTAA1 genes involved in the auxin biosynthesis pathway. We made nine CRISPR/Cas9 constructs with ...